June 22, 2015; Vancouver, BC and Sherbrooke, Quebec: The Centre for Drug Research and Development (CDRD), Canada’s fully-integrated national drug development and commercialization centre, and the Université de Sherbrooke are pleased to announce they have finalized an agreement to establish a new drug development hub in Quebec called the Sherbrooke-ACCESS-CDRD Node. The “ACCESS” node, an acronym for “ACCelerateur biopharmaceutique de I’ES(S)trie)” will reside in the Institut de pharmacologie de Sherbrooke (IPS) located on the Health Campus of the Université de Sherbrooke.
The ACCESS node will focus on collaborative health-related projects in areas such as pain and inflammation utilizing IPS’s expertise in human disease modeling, imaging technology and medicinal chemistry. CDRD will work with IPS to advance research discoveries towards commercialization and clinical applications thus enhancing its drug development infrastructure and expertise in Quebec to further support Canadian health researchers. “For IPS it is an important step ahead in terms of exploiting our unique expertise and technological platforms for our region, for Quebec, as well as being better networked across Canada” mentioned IPS Director, Eric Marsault.
President and CEO of CDRD, Karimah Es Sabar commented, “We are excited to be increasing our presence and partnerships in Quebec. This newest collaboration is just one example of how CDRD is strengthening drug development and commercialization opportunities and supporting enhanced national R&D capacity through our pan-Canadian network. By working with the leading experts at the Université de Sherbrooke, we will make an even greater level of resources available to Canadian researchers looking to advance their early-stage health-related discoveries towards commercialization.”
“Together with CDRD’s expertise, the IPS will strengthen its position as a leader in developing tomorrow’s medicine. This agreement is a testament to the quality of our installations and the extensive knowledge of our research teams that is now recognized worldwide. The combined expertise of our two organizations will undoubtedly allow maximum use of our resources and certainly lead to tangible benefits for the public.” commented Jean-Pierre Perreault, vice-dean at the Faculty of Medicine and Health Sciences of the Université de Sherbrooke.
The Sherbrooke-ACCESS-CDRD Node is the third agreement to further CDRD’s pan-Canadian network of CDRD drug development nodes. The other two are the Metabolomics Node at the University of Alberta and the Atlantic Node at Dalhousie University/IWK Health Centre.
– 30 –
The Centre for Drug Research and Development (CDRD)
604-827-1226 | email@example.com
Faculty of Medicine and Health Sciences | Université de Sherbrooke
819-821-8000, extension 72751 | Maryse.Provencal@USherbrooke.ca
About the Centre for Drug Research and Development
The Centre for Drug Research and Development (CDRD) is Canada’s fully-integrated national drug development and commercialization centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. Our mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector — thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). For more information: www.cdrd.ca
About the Institut de pharmacologie de Sherbrooke
Founded in 1997, the Institut de pharmacologie de Sherbrooke (IPS) is located on the health-sciences campus and is rooted in two fields in which the Université de Sherbrooke has distinguished itself internationally: pharmacology and organic chemistry. Today, the IPS brings together 33 researchers and their research teams from 10 departments and 3 faculties (medicine and health sciences, science, and engineering). Since its creation, the IPS has fostered the expansion of its interdisciplinary collaborations in developing medications and diagnostic agents as well as validating potentially therapeutic and/or diagnostic targets and technologies aimed at improving these processes. The institute is also an incubator allowing for the emergence of innovative technologies with high market potential. Visit our website: USherbrooke.ca/ips.